Blog

Blog

Drug Target Encyclopedia Series (3) — FXTD3

Linkedin

Release Time：

2025-12-03 15:27

 

FXYD3 (also known as Mat-8 or Phosphohippolin) is a small transmembrane protein that regulates ion transport, particularly by modulating the Na+/K+-ATPase pump. Overexpressed in multiple cancers—including breast, prostate, and gastric tumors—FXYD3 plays a critical role in maintaining cellular homeostasis and promoting tumor survival, making it a compelling target for oncology research.

Unlike broader ion channel regulators, FXYD3’s selective overexpression in malignant tissues offers a potential avenue for precision therapy, minimizing off-target effects. Its involvement in cell proliferation, migration, and chemoresistance underscores its importance in cancer progression and treatment resistance.

Emerging Therapeutic Strategies Targeting FXYD3

While no FDA-approved drugs currently target FXYD3 directly, innovative approaches are under investigation:

  • Monoclonal antibodies (mAbs) – Designed to block FXYD3’s interaction with Na+/K+-ATPase, disrupting tumor cell metabolism.
  • siRNA/gene silencing – Suppressing FXYD3 expression to impair cancer cell survival and enhance chemo-sensitivity.
  • Small-molecule inhibitors – Targeting FXYD3’s regulatory function to destabilize tumor microenvironments.

Beyond oncology, FXYD3’s role in electrolyte balance and cellular stress responses suggests potential applications in cardiovascular and metabolic disorders.

The next wave of FXYD3 research aims to validate its therapeutic potential, optimize targeting strategies, and explore combination therapies for improved efficacy.

Need FXYD3 tools for drug discovery?

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

Prev

Drug Target Encyclopedia Series (4) — CD8

Drug Target Encyclopedia Series (2) — BCMA

Next